Practice
Featured experience
Comcast spinoff of select cable television networks
We are advising Comcast on the transaction
Durational Capital Management strategic investment in Garage Beer
We are advising Durational Capital Management on the transaction
Arcos Dorados renewal of long-term master franchise agreement with McDonald’s
We advised Arcos Dorados on the transaction
GSK strategic alliance with Vesalius Therapeutics
We advised GSK on the transaction
Pure Storage $425 Million Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 25,000,000 shares of Class A common…
Davis Polk Advises Fandango on Its Acquisition of Ingresso.com
Davis Polk is advising Fandango in connection with its acquisition of Ingresso.com from B2W Companhia Digital, a Latin…
Davis Polk Advises Penumbra, Inc. on Its $138 Million Initial Public Offering
Davis Polk advised Penumbra, Inc. on its SEC-registered initial public offering of 4,600,000 shares of common stock for an…
Davis Polk Advises Dialog Semiconductor on Its Acquisition of Atmel
Davis Polk is advising Dialog Semiconductor plc in connection with its $4.6 billion acquisition of Atmel Corporation…
Davis Polk Advises MSCI on Its Acquisition of Insignis
Davis Polk is advising MSCI Inc. in connection with its acquisition of all of the assets of Insignis, Inc. Financial terms…
Davis Polk Advises SS&C on Its Acquisition of Primatics Financial
Davis Polk is advising SS&C Technologies Holdings, Inc. in connection with its approximately $122 million acquisition of…
Davis Polk Advises Roper Technologies on Its Acquisition of RF IDeas
Davis Polk advised Roper Technologies, Inc. in connection with its acquisition of RF IDeas, Inc. The financial terms of the…
Davis Polk Advises SS&C on Its Acquisition of Citigroup’s Alternative Investor Services Business
Davis Polk is advising SS&C Technologies Holdings, Inc. in connection with its acquisition of Citigroup’s Alternative…
Global Blood Therapeutics, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers in connection with the $138 million initial public offering of common…
Aimmune Therapeutics, Inc. $183.9 Million Initial Public Offering
Davis Polk advised the underwriters in connection with the $183.9 million initial public offering of Aimmune Technologies,…